Denali Therapeutics Inc. Jefferies Global Healthcare Conference - DENALI THERAPEUTICS INC
Financial Performance:
- U.S. launch of Avlea (Hunter Syndrome) is exceeding internal expectations, with no specific revenue figures provided for Q2-Q3, but Q4 2024 revenue guidance set at $30–32 million.
- Annual price for Avlea is approximately $800,000 for a 30kg patient in the U.S., representing a 60% premium over the competitor Elaprase ($500,000).
- Management projects revenues will eventually exceed current Elaprase global sales of ~$700 million, contingent on label expansion and international approvals.
- No specific cash flow, debt, or margin data was disclosed in the transcript.
- Revenue runway is being extended by the commercial success of Avlea, which validates the transport vehicle platform for future product launches.
Guidance and Future Outlook:
- Provided specific quarterly revenue guidance for 2026 ($30–32M range implied for the launch trajectory) to illustrate growth trajectory; 2027 guidance not yet disclosed.
- BLA filing for Sanfilippo (MPS III) targeting acceleration in 2026, with Phase 2 data presentation expected at World 2027.
- Progranulin (FTD) program aims for data readout in the first half of 2027; treatment duration extended from 6 to 12 months to better assess biomarkers.
- Alzheimer's Tau program expects CSF data and dosing identification in 2027, followed by efficacy studies; A-beta (DNL921) targets early biomarker data in 2027.
- Long-term goal is to expand Avlea label to adults (25% of population, 30%+ value due to weight-based dosing) and secure international approvals via the COMPAS study.
Business Segments and Product Lines:
- Avlea (Hunter Syndrome): First approved product utilizing the transport vehicle to cross the blood-brain barrier; currently focused on pediatric population (75% of 500 U.S. patients).
- Sanfilippo (MPS III): Phase 2 data shows 80% average reduction in CSF heparan sulfate and normalization in a subset; 20-patient dataset to be presented at World 2027.
- Frontotemporal Dementia (Progranulin): Protein replacement therapy for patients with granulin mutations (6–10% of FTD population); mechanism similar to ERT portfolio.
- Alzheimer's: Two programs targeting Tau (DNL201) and A-beta (DNL921) using the transport vehicle for even brain distribution; DNL921 features an "on-off switch" to reduce hematological risks.
- Pompe & FTD: Mentioned as part of the broader pipeline with upcoming readouts, though less detail provided than Hunter/Sanfilippo/Alzheimer's.
- COMPAS Study: Confirmatory Phase 3 for Hunter Syndrome (head-to-head vs. Elaprase) with 65 patients; targets two-year endpoint completion end of next year with readout in 2028.
Market and Competitive Landscape:
- Hunter Syndrome global market: ~2,000 total patients (500 U.S., 1,500 ex-U.S.); aiming to achieve dominant market share by treating both prevalent and new patients.
- Competitor Elaprase is non-brain penetrant; Denali differentiates via brain penetration and superior biomarker changes (e.g., NFL normalization).
- Alzheimer's landscape is shifting with recent gene therapy approvals (e.g., Ultragenyx); Denali aims to leverage integrated TFR binding for superior biodistribution and tolerability compared to intrathecal delivery or conventional linker-based antibodies.
- International expansion strategy: 1/3 of ex-U.S. markets may allow accelerated pathways without a Phase 3 study, relying on U.S. approval data.
Risks and Challenges:
- Regulatory hurdles remain for international approvals and the need for pricing/reimbursement strategies post-approval in ex-U.S. markets.
- Antigenicity (anti-drug antibodies) observed in Sanfilippo patients who did not normalize biomarkers, a common challenge in ERT therapies.
- Clinical heterogeneity in Sanfilippo and Hunter populations; study design must account for severity levels and age-related developmental curves.
- Uncertainty regarding the exact biomarker reduction thresholds required for accelerated approval in FTD and Alzheimer's, pending FDA engagement.
- Enrollment challenges in rare disease trials, mitigated by the use of historical natural history data (influenced by new gene therapy precedents).
Management Commentary and Tone:
- Tone is highly confident and optimistic, emphasizing the "validity" of the transport vehicle platform following the Avlea launch.
- Management expresses urgency regarding the "window of opportunity" to treat patients before developmental decline, particularly in Sanfilippo and Hunter.
- CEO Ryan Watts and CFO Alex Shuth (via Q&A) projected a strong commercial trajectory, expecting Avlea to outperform the current standard of care globally.
- Management highlighted the strategic advantage of subcutaneous dosing as a future goal for all programs to facilitate prevention and ease of use.
Analyst Questions and Answers:
- Pricing: Confirmed 60% premium over Elaprase in the U.S. ($800k vs. $500k annually for a 30kg patient).
- Market Size: Confirmed total U.S. Hunter patients at ~500 (375 eligible under current label); Sanfilippo opportunity estimated similar to Hunter despite harder prevalence gauging.
- COMPAS Data: Study will include adult cohorts (somatic endpoints) and children (neurologic endpoints); Vineland behavioral endpoints are primary co-primary measures alongside HS biomarkers.
- Sanfilippo Efficacy: Initial data showed 80% CSF heparan sulfate reduction; 20-patient dataset will include the marketed dose group.
- FDA Alignment: Engaging with FDA regarding shifting efficacy bars due to gene therapy approvals (e.g., Ultragenyx); comparing against baseline rather than historical control for confirmatory studies.
- Alzheimer's Dosing: Tau program targets 20–50% reduction; A-beta program uses healthy volunteers to assess "off" switch (hematology) before moving to Alzheimer's patients for "on" switch (plaque reduction).
Other Key Points:
- The transport vehicle platform is now considered "validated" by Avlea, enabling application across a broader pipeline including enzymes, antibodies, and ASOs.
- Avlea's mechanism allows for even distribution throughout the brain, contrasting with the uneven distribution of intrathecal injections seen in other programs (e.g., Ionis/Alnylam).
- DNL921 (A-beta) utilizes an integrated TFR binding mechanism to prevent immune system engagement when bound, reducing reticulocyte effects and improving stability compared to linker-based molecules.
- Management confirmed that the Phase 3 for Sanfilippo will be open-label (no standard of care) and will compare against baseline, adapting to the changing landscape of rare disease trials.
- Company
- DENALI THERAPEUTICS INC
- Keywords
- DENALI THERAPEUTICS INC